Galenica AG/€GALE
1D1W1MYTD1Y5YMAX
Capital at risk
About Galenica AG
Galenica AG is a healthcare company based in Switzerland, with a core focus on the health and pharmacy sector. The company operates through two main segments: Health & Beauty and Services. The Health & Beauty segment includes the operation of pharmacies and the distribution of health products, while the Services segment provides logistics and related services for the Swiss healthcare sector. Founded in 1927, Galenica has evolved to become a key player in the Swiss market with a comprehensive network and infrastructure that facilitate efficient healthcare distribution. Its strategic positioning is enhanced by its extensive logistics capabilities and strong presence within Switzerland, headquartered in Bern.
- Ticker
- €GALE
- Sector
- Health
- Primary listing
- XGAT
- Employees
- 6,623
- Headquarters
- Bern, Switzerland
- Website
- www.galenica.com
Galenica AG Metrics
BasicAdvanced
€4.3B
25.88
€3.37
0.28
€2.71
1.55%
Price and volume
Market cap
€4.3B
Beta
0.28
52-week high
€105.30
52-week low
€86.15
Average daily volume
92K
Dividend rate
€2.71
Financial strength
Current ratio
1.07
Quick ratio
0.642
Long term debt to equity
0.54
Total debt to equity
0.783
Dividend payout ratio (TTM)
78.72%
Interest coverage (TTM)
13.90%
Profitability
EBITDA (TTM)
270.533
Gross margin (TTM)
12.46%
Net profit margin (TTM)
3.71%
Operating margin (TTM)
4.77%
Effective tax rate (TTM)
17.18%
Revenue per employee (TTM)
€687,720
Management effectiveness
Return on assets (TTM)
4.00%
Return on equity (TTM)
11.36%
Valuation
Price to earnings (TTM)
25.883
Price to revenue (TTM)
0.96
Price to book
2.91
Price to tangible book (TTM)
-230.21
Price to free cash flow (TTM)
21.535
Free cash flow yield (TTM)
4.64%
Free cash flow per share (TTM)
4.054
Dividend yield (TTM)
3.11%
Forward dividend yield
1.55%
Growth
Revenue change (TTM)
6.39%
Earnings per share change (TTM)
-17.39%
3-year revenue growth (CAGR)
5.09%
3-year earnings per share growth (CAGR)
-16.06%
3-year dividend per share growth (CAGR)
4.35%
Bulls say / Bears say
Switzerland’s Galenica 2025 sales rose 5.5% to CHF 4,135.6 million, and the group expects 2026 sales growth of 5%–7%, underlining resilient demand and management confidence. (Reuters)
Galenica achieved a 7.3% increase in net sales to CHF 1,409.7 million in the first four months of 2026, with home care revenue up 9.1% and diagnostics contributing CHF 40.8 million, demonstrating successful segment diversification. (Reuters)
In H1 2026, Galenica’s revenue rose 7.1% to CHF 2,136.5 million and adjusted EBIT also increased 7.1% to CHF 117.7 million, reflecting robust operational execution and confirming full-year guidance. (MarketScreener)
Galenica’s physicians wholesale segment grew only 1.0% in H1 2026—well below the 3.1% market increase—due to a product range adjustment, highlighting vulnerability in this key channel. (MarketScreener)
Galenica decided to close production at its Bichsel subsidiary by end-2026, reducing 152 jobs and likely incurring special costs and transition risks. (Reuters)
In April 2026, Swissmedic fined Amavita and Sun Store pharmacies (operated by Galenica) for a Covid-19 vaccine advertising slogan that breached legal requirements, exposing the group to regulatory and reputational risk. (Keystone-SDA)
Data summarised monthly by Lightyear AI. Last updated on 29 Aug 2026.
Upcoming events
No upcoming events
Funds containing Galenica AG
AllEURGBP
Fund name | Fund size | €GALE weighting |
|---|---|---|
Xtrackers MSCI Europe Small Cap€DX2J | €3.2B | 0.32% |
Xtrackers MSCI Europe Small Cap£XXSC | £2.8B | 0.32% |
Amundi STOXX Europe 600£MEUD | £6.6B | 0.04% |
Amundi STOXX Europe 600 ESG€C6E | €735M | 0.04% |
Amundi STOXX Europe 600€MEUD | €7.6B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.